Brand names: Atovaquone And Proguanil Hydrochloride
3 interactions on record
7.5 Indinavir Concomitant administration of atovaquone and indinavir did not result in any change in the steady-state AUC and C max of indinavir but resulted in a decrease in the C trough of indinavir [see Clinical Pharmacology (12.3) ] . Caution should be exercised when prescribing atovaquone with indinavir due to the decrease in trough concentrations of indinavir.
Source: FDA drug label - atovaquone and proguanil hydrochloride
7.4 Metoclopramide While antiemetics may be indicated for patients receiving atovaquone and proguanil hydrochloride tablets, metoclopramide may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available [see Clinical Pharmacology (12.3) ] .
Source: FDA drug label - atovaquone and proguanil hydrochloride
( 7.2 ) Tetracycline may reduce atovaquone concentrations; parasitemia should be closely monitored. 7.3 Tetracycline Concomitant treatment with tetracycline has been associated with a reduction in plasma concentrations of atovaquone [see Clinical Pharmacology (12.3) ] . Parasitemia should be closely monitored in patients receiving tetracycline.
Source: FDA drug label - atovaquone and proguanil hydrochloride